Table 2.
Mean change for Q-LES-Q SF percentage maximum scores from baseline to 6 weeks: monotherapy (Lurasidone 20–60 mg/day and Lurasidone 80–120 mg/day)
| Lurasidone 20–60 mg/day | Lurasidone 80–120 mg/day | |||||
|---|---|---|---|---|---|---|
| N Mean (SD) | N Mean Change (SD) | P value | N Mean (SD) | N Mean Change (SD) | P value | |
| Q-LES-Q SF | ||||||
| Baseline | 157 33.8 (13.7) | -- | 160 33.5 (13.0) | -- | ||
| 6-Weeks | 123 55.9 (19.4) | 120 21.9 (16.0) | <.0001 | 121 56.8 (18.1) | 120 23.0 (17.7) | <.0001 |
All p-values for Q-LES-Q SF outcomes are based on t-tests comparing differences from baseline to 6 weeks within treatment group